143 related articles for article (PubMed ID: 17881663)
1. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis.
Hettema ME; Zhang D; Bootsma H; Kallenberg CG
Ann Rheum Dis; 2007 Oct; 66(10):1398-9. PubMed ID: 17881663
[No Abstract] [Full Text] [Related]
2. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe Raynaud's phenomenon with bosentan in a patient with systemic sclerosis.
Dunne J; Dutz J; Shojania K; Ng B; van Eeden S
Rheumatology (Oxford); 2006 Jul; 45(7):911-2. PubMed ID: 16531439
[No Abstract] [Full Text] [Related]
4. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon.
Moore TL; Vail A; Herrick AL
Rheumatology (Oxford); 2007 Feb; 46(2):363-4. PubMed ID: 17116656
[No Abstract] [Full Text] [Related]
5. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis.
Ramos-Casals M; Brito-Zerón P; Nardi N; Claver G; Risco G; Parraga FD; Fernandez S; Julià M; Font J
Rheumatology (Oxford); 2004 Nov; 43(11):1454-6. PubMed ID: 15502001
[No Abstract] [Full Text] [Related]
6. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
[TBL] [Abstract][Full Text] [Related]
7. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
Nishibu A; Sakai E; Oyama N; Yamamoto T
Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of bosentan in the treatment of Raynaud's phenomenon in patients with systemic sclerosis never treated with prostanoids.
Parisi S; Bruzzone M; Centanaro Di Vittorio C; Laganà A; Peroni CL; Fusaro E
Reumatismo; 2014 Mar; 65(6):286-91. PubMed ID: 24705032
[TBL] [Abstract][Full Text] [Related]
9. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
Cestelli V; Manfredi A; Sebastiani M; Praino E; Cannarile F; Giuggioli D; Ferri C
Mod Rheumatol; 2017 Jan; 27(1):110-114. PubMed ID: 27310203
[TBL] [Abstract][Full Text] [Related]
10. Influence of bosentan on fingertip rewarming in patients with systemic sclerosis.
Autenrieth J; Riemekasten G; Bert C; Worm M
J Dtsch Dermatol Ges; 2013 Apr; 11(4):356-9. PubMed ID: 23419126
[No Abstract] [Full Text] [Related]
11. Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis.
Kurgyis Z; Varga R; Sick I; Lang MU; Ruzicka T; Sárdy M
Acta Derm Venereol; 2011 Oct; 91(6):716-7. PubMed ID: 21879251
[No Abstract] [Full Text] [Related]
12. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
Rosato E; Molinaro I; Borghese F; Rossi C; Pisarri S; Salsano F
J Rheumatol; 2010 Dec; 37(12):2531-9. PubMed ID: 20810512
[TBL] [Abstract][Full Text] [Related]
13. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
[TBL] [Abstract][Full Text] [Related]
14. Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment.
Kumar N; Griffiths B; Allen J
J Rheumatol; 2006 Sep; 33(9):1918-9. PubMed ID: 16960964
[No Abstract] [Full Text] [Related]
15. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
16. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
Gore J; Silver R
Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
[No Abstract] [Full Text] [Related]
17. Treatment of Raynaud's phenomenon with captopril.
Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
[TBL] [Abstract][Full Text] [Related]
18. [Use of defibrotide in the treatment of Raynaud's phenomenon associated with progressive systemic sclerosis or essential mixed cryoglobulinemia].
Ranieri G; De Mitrio V; Petronelli M; Ancona A; Dammacco F
Clin Ter; 1988 Sep; 126(5):335-43. PubMed ID: 2973963
[No Abstract] [Full Text] [Related]
19. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
[TBL] [Abstract][Full Text] [Related]
20. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
Surwit RS; Gilgor RS; Allen LM; Duvic M
Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
